Literature DB >> 19183430

Hypothalamo-pituitary-adrenal axis activity after intracranial catastrophies: what is enough?

A B Johan Groeneveld1, Albertus Beishuizen, Nienke Molenaar.   

Abstract

This commentary on a paper by Bendel and colleagues in the previous issue of Critical Care describes the difficulty in assessing the sufficiency of adrenal responses to endogenous, stress-induced adrenocorticotropic hormone (ACTH) release by the pituitary or to exogenous ACTH administration in the critically ill patient in general, and after subarachnoid hemorrhage in particular. It is argued that comparisons with responses under circumstances of equal stress as well as assessments of severity of disease are necessary to judge the sufficiency of cortisol responses to endogenous and exogenous ACTH before treatment is considered. There are no universally applicable cutoff values for cortisol levels--and increases in cortisol levels with increasing levels of ACTH--for the diagnosis of relative adrenal insufficiency (or as it is now commonly termed, critical illnes-related corticosteroid insufficiency) following, for example, subarachnoid hemorrhage or other intracranial catastrophes. The paper by Bendel and colleagues is critically discussed in view of these concepts.

Entities:  

Mesh:

Year:  2009        PMID: 19183430      PMCID: PMC2688095          DOI: 10.1186/cc7131

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


The expression 'enough is enough' refers to the idea that we can unambiguously decide on what is sufficient in life. The question is whether this also applies to medicine and science, where uncertainties may outweigh certainties. In the previous issue of Critical Care, the sufficiency of hypothalamo-pituitary-adrenal (HPA) function over time following subarachnoid hemorrhage (SAH) is addressed [1]. We interpret the findings by the authors on the basis of increases in circulating adrenocorticotropic hormone (ACTH), but not of circulating cortisol, with increasing clinical severity of SAH, and that some (relative) adrenal insufficiency is present in severely afflicted patients in the acute phase, compared to controls, even though the study does not allow one to determine whether controls (after aneurysm surgery) were equally stressed. In any case, lower cortisol levels than in acute SAH patients suggest lower stress levels. A comparison with the literature is hard, since there are very few data on acute HPA axis activity after SAH [2]. Indeed, expected responses to stress – caused, for instance, by intracranial catastrophes such as traumatic brain injury and SAH – would include increases in endogenous ACTH and, thereby, in cortisol secretion relative to normal, unstressed levels, with a concomitant elevation of circulating (total and free) cortisol levels [2-5]. Sufficient adaptation to the stress response would be suggested by parallel increases in ACTH and cortisol levels acording to the degree of stress associated with the severity of disease (assessed by scoring systems) [2,6,7]. The ratio between ACTH levels and free cortisol levels, which is expected to be maintained because of feedback activity, could provide an index of adrenal sensitivity to ACTH [5]. Adrenal sensitivity can increase with prolonged stress-induced ACTH stimulation or release of stimulating factors other than ACTH, which cause the ratio to decrease; on the other hand, an increase in the ratio would denote adrenal insensitivity and thus perhaps insufficiency, as the paper by Bendel and colleagues [1] seems to suggest. However, (even free) cortisol levels in serum do not necessarily accurately reflect the rate of adrenal cortisol secretion, and the additive value of determinations of free cortisol levels for the interpretation of the sufficiency of response (to disease severity and/or endogenous ACTH) remains unclear [3,4], as is the case in the paper by Bendel and colleagues [1]. When (in)sufficiency of HPA axis activation and ACTH/cortisol secretion is suspected for a given severity of disease, additional assessment of responses to stimulation tests for determining sensitivity may provide further information with which to judge deviations from non-stressed normality [5]. The response to additional stress can be mimicked by ACTH stimulation, even though (surgical) stress may increase free cortisol levels more than a supraphysiological dose of ACTH [4]. This implies that HPA axis sufficiency can be judged by assessing the sensitivity of adrenal responses to endogenous and exogenous ACTH, the levels of which are determined by the severity of disease and direct stimulation, respectively, and which frequently interrelate in a reciprocal manner [5,7]. For instance, high baseline (free) cortisol levels associated with severe stress may be associated with some decrease in delta cortisol levels upon ACTH stimulation. Therefore, there are no fixed and universally applicable cutoff points to separate insufficient from sufficient adrenal responses in the critically ill, depending on severity of disease. Hence, although delta cortisol cutoff values have been found to be predictive for (survival) benefits of hydrocortisone treatment in septic shock [7], their use for non-septic patients, including those with SAH, as was done in the paper by Bendel and colleagues and other papers [1,8], makes little sense. Even though similar responses in acute SAH patients and controls [1] suggest sufficient adrenal responses after SAH, we do not know whether the responses depended on the clinical severity of SAH. Otherwise, sliding responses may contribute to poor acceptance of the ACTH test for adrenocortical function during critical illness. The causes and consequences, and thus the clinical signficance, of the proposed relative adrenal insufficiency after SAH as suggested by Bendel and colleagues [1] remain obscure. In any case, patients on etomidate, well known for its suppressive action on the adrenals, were excluded from the study by Bendel and colleagues. Corticosteroids given in the acute phase of SAH do not afford a survival benefit [9], even though hydrocortisone treatment may attenuate hyponatremia, which commonly develops during the course of disease and therapy with hypervolemia and is often attributed to cerebral salt waisting [10]. Nevertheless, the clinical manifestations of relative adrenal insufficiency in the setting of SAH are largely unknown and require future investigation, but might include vasopressor-insensitive hypotension and hyponatremia in the acute phase. However, the study by Bendel and colleagues [1] does not suggest such associations. As a late complication in the disease course after SAH and the resultant damage, secondary HPA axis insufficiency may supervene when the stress of the acute phase has waned and ACTH release by the pituitary still seems insufficient [2,11-14]. In the study by Bendel and colleagues [1], a follow-up assessment was made at 3 months in SAH survivors and little evidence for secondary HPA insufficiency was found, in contrast to previous observations, suggesting that insufficiency may be transient in the long term [11-14]. Indeed, some authors suggest that weight gain, growth hormone and gonadal deficiencies in the chronic phase could be explained by (pan)hypopituitarism [2,11-14]. In contrast, low (that is, subnormal) ACTH and cortisol levels early in the course of SAH in the study by Bendel and colleagues [1] could have been caused by (transient) secondary HPA insufficiency, as also found by others [2,5]. Taken together, the sufficiency of the HPA stress response to intracranial catastrophies remains hard to establish, as exemplified in the paper by Bendel and colleagues [1]. We propose that for judging adrenal sensitivity, HPA (in)sufficiency should be defined in terms of both clinical and laboratory (ab)normalities. The authors of the current paper on SAH [1] only partly succeed in applying the above concepts and potential HPA insufficiency after SAH remains open for further study.

Abbreviations

ACTH: adrenocorticotropic hormone; HPA: hypothalamo-pituitary-adrenal; SAH: subarachnoid hemorrhage.

Competing interests

The authors declare that they have no competing interests.
  14 in total

1.  Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study.

Authors:  Gianluca Aimaretti; Maria Rosaria Ambrosio; Carolina Di Somma; Maurizio Gasperi; Salvatore Cannavò; Carla Scaroni; Alessandra Fusco; Patrizia Del Monte; Ernesto De Menis; Marco Faustini-Fustini; Franco Grimaldi; Francesco Logoluso; Paola Razzore; Silvia Rovere; Salvatore Benvenga; Ettore Ciro Degli Uberti; Laura De Marinis; Gaetano Lombardi; Franco Mantero; Enio Martino; Giulio Giordano; Ezio Ghigo
Journal:  J Clin Endocrinol Metab       Date:  2005-09-06       Impact factor: 5.958

2.  High incidence of neuroendocrine dysfunction in long-term survivors of aneurysmal subarachnoid hemorrhage.

Authors:  Ioanna Dimopoulou; Andreas T Kouyialis; Marinella Tzanella; Apostolos Armaganidis; Nikolaos Thalassinos; Damianos E Sakas; Stylianos Tsagarakis
Journal:  Stroke       Date:  2004-10-21       Impact factor: 7.914

Review 3.  Corticosteroids for aneurysmal subarachnoid haemorrhage and primary intracerebral haemorrhage.

Authors:  V L Feigin; N Anderson; G J E Rinkel; A Algra; J van Gijn; D A Bennett
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

4.  The low-dose corticotropin stimulation test in acute traumatic and non-traumatic brain injury: incidence of hypo-responsiveness and relationship to outcome.

Authors:  Ioanna Dimopoulou; Stylianos Tsagarakis; Evangelia Douka; Maria Zervou; Andreas T Kouyialis; Urania Dafni; Nikolaos Thalassinos; Charis Roussos
Journal:  Intensive Care Med       Date:  2004-04-21       Impact factor: 17.440

Review 5.  Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review.

Authors:  Harald Jörn Schneider; Ilonka Kreitschmann-Andermahr; Ezio Ghigo; Günter Karl Stalla; Amar Agha
Journal:  JAMA       Date:  2007-09-26       Impact factor: 56.272

6.  Prevalence of pituitary deficiency in patients after aneurysmal subarachnoid hemorrhage.

Authors:  Ilonka Kreitschmann-Andermahr; Christine Hoff; Bernhard Saller; Sandra Niggemeier; Sabine Pruemper; Bernd O Hütter; Veit Rohde; Axel Gressner; Siegfried Matern; Joachim M Gilsbach
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

7.  Relative adrenal insufficiency as a predictor of disease severity, mortality, and beneficial effects of corticosteroid treatment in septic shock.

Authors:  Margriet F C de Jong; Albertus Beishuizen; Jan-Jaap Spijkstra; A B Johan Groeneveld
Journal:  Crit Care Med       Date:  2007-08       Impact factor: 7.598

8.  A randomized controlled trial of hydrocortisone against hyponatremia in patients with aneurysmal subarachnoid hemorrhage.

Authors:  Yoichi Katayama; Jo Haraoka; Hidehiro Hirabayashi; Tatsuro Kawamata; Keiji Kawamoto; Takao Kitahara; Jun Kojima; Toshihiko Kuroiwa; Tatsuro Mori; Nobuhiro Moro; Izumi Nagata; Akira Ogawa; Kikuo Ohno; Yoshikatsu Seiki; Yoshiaki Shiokawa; Akira Teramoto; Teiji Tominaga; Toshiki Yoshimine
Journal:  Stroke       Date:  2007-06-21       Impact factor: 7.914

9.  Measurement of serum free cortisol shows discordant responsivity to stress and dynamic evaluation.

Authors:  Mirjam Christ-Crain; Sukhdeep Jutla; Isabelle Widmer; Orestes Couppis; Caroline König; Hans Pargger; Jardena Puder; Ray Edwards; Beat Müller; Ashley B Grossman
Journal:  J Clin Endocrinol Metab       Date:  2007-03-06       Impact factor: 5.958

10.  Pituitary-adrenal function in patients with acute subarachnoid haemorrhage: a prospective cohort study.

Authors:  Stepani Bendel; Timo Koivisto; Esko Ruokonen; Jaakko Rinne; Jarkko Romppanen; Ilkka Vauhkonen; Vesa Kiviniemi; Ari Uusaro
Journal:  Crit Care       Date:  2008-10-13       Impact factor: 9.097

View more
  1 in total

1.  Statins in the critically ill.

Authors:  Isabelle De Loecker; Jean-Charles Preiser
Journal:  Ann Intensive Care       Date:  2012-06-18       Impact factor: 6.925

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.